Non-small cell lung cancer therapeutics: Key market research findings
- Increased awareness towards cancer campaigns and promotion of patient assistance programs
- Entry of new drugs and therapies
Technavio has added a new market research report on the global non-small cell lung cancer therapeutics market, to its lung cancer portfolio. Technavio’s market research analysts estimate the non-small cell lung cancer therapeutics market to grow at a CAGR of around 7% between 2015 and 2019 due to the presence of a strong pipeline drugs and launch of novel therapies. The Americas dominate the global market for non-small cell lung cancer therapeutics, occupying around 45% of the total market share. Increased focus towards patient assistance programs and increased accessibility to treatment therapies are propelling this region’s market growth.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments.
“Various organizations worldwide are conducting campaigns and aware programs such as ‘Shine a Light’ about non-small cell lung cancer. November is marked as the lung cancer awareness month across the world. The US’ Lung Cancer Alliance supports cancer patients by offering easy accessibility to medicines and effective reimbursement for diagnosis and tests. Also, it aids the lung cancer-related research programs,” says Imran Mushtaq, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
The market is witnessing the launch of various new drugs for the treatment of non-small cell lung cancer therapeutics. Current therapies do not provide permanent cure to the disease and are effective in initial stages only. Onartuzumab, necitumumab, and selumitinib, some promising late-stage pipeline products that are expected to get approval during the forecast period.
The major players in the global non-small cell lung cancer therapeutics market include AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche, and Pfizer. This market is expected to grow rapidly due to new product launches and the presence of strong pipeline drugs. Since this market is fragmented, it is highly competitive. The market vendors compete with each other to innovate drugs that can effectively treat and cure non-small cell lung cancer.
A more detailed analysis is available in the Technavio report, Global Non-small Cell Lung Cancer Therapeutics Market 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other Related Reports:
- Global Non-small Cell Lung Cancer Market 2014-2018
- Global Non-small Cell Lung Cancer Drugs Market 2012-2016
- Global Lung Cancer Therapeutics Market 2015-2019
- Global Small Cell Lung Cancer Therapeutics Market 2015-2019
Further Reading:
